Published on
Jul 3, 2025
FDA Grants Accelerated Approval to ZEGFROVY, First Oral EGFR‑Exon‑20 Insertion NSCLC Therapy
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to ZEGFROVY (sunvozertinib), a novel oral therapy developed by Dizal, for the treatment of adults with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring …
Source:
Pharma Journalist
-
Neutral
